Synthesis and Anti-HIV Activity of 4-Chloro-2-mercapto-N-(1,4,5,6-tetrahydro-1,2,4-triazin-3-yl)benzenesulfonamide Derivatives

• Autorzy: Pomarnacka E.
• Języki publikacji: EN

Abstrakty

EN

The synthesis of 4-chloro-2-mercapto-N-(1,5-dimethyl- or 1-alkyl-1,4,5,6-tetrahydro- 1,2,4-triazin-3-yl)benzenesulfonamides 15-28 is described. Suggested mechanism of the investigated reaction is discussed. The compounds 15-17 and 19 were tested for their in vitro anti-HIV potency at the National Cancer Institute and only 4-chloro-2- mercapto-N-(1-methyl-1,4,5,6-tetrahydro-1,2,4-triazin-3-yl)benzenesulfonamide (15) showed reasonable activity (TI50 = 6.21).

Słowa kluczowe

EN

4-chloro-2-mercapto-N-(1,4,5,6-tetrahydro-1,2,4-triazin-3-yl)benzenesulfonamide derivatives; synthesis; anti-HIV activity

• Wydawca: Polskie Towarzystwo Chemiczne
• Czasopismo: Polish Journal of Chemistry
• Rocznik: 2007
• Tom: Vol. 81, nr 3
• Strony: 345--352
• Opis fizyczny: Bibliogr. 21 poz., rys.

Twórcy

autor

Pomarnacka E.

• Department of Chemical Technology of Drugs, Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416 Gdańsk, Poland

Bibliografia

• 1. Huang L., Ho P., Lee K-H. and Chen CH-H., Bioorg. Med. Chem., 14, 2279 (2006).
• 2. Sriram D., Vogeswari P, Myneedu N.S. and Sarawat V., Bioorg, Med. Chem. Lett., 16, 2127 (2006).
• 3. Surleraux D., Tahri A., Verschueren W.G., Pille G., de Kock H.A., Pauwels R., Wigerinck R, Jonckers T., King N. and Schiffer C., J. Med. Chem., 48, 1813 (2005).
• 4. Neamati N., Mazumder A., Owen J.M., Schultz R.J, Sunder S. and Pommier V., Antiviral Chem. Chemother.,8,485(l997).
• 5. Nagarajan S.R., De Crescenzo G.A, Getman D.R, Lu H., Sikorski J., Walker J.L., McDonald J.J.,Houseman K., Kocan G.R, Kishore N., Mehta P.P., Funkes-Shippy Ch. and Blystone L., Bioorg. Med. Chem., 11, 4769 (2003).
• 6. Miller J.F., Furfine E.S., Hanlon M.H., Hazen R.J., Ray J., Robinson L., Samano V. and Spaltenstein A., Bioorg. Med. Chem. Lett., 14, 959 (2004).
• 7. Brzozowski Z., Acta Polon. Pharm. Drug. Res., 55, 49 (1998).
• 8. Pomarnacka E., Acta Polon. Pharm. Drug. Res., 55, 481 (1998).
• 9. Pomarnacka E. and Kórnicka A., Farmaco, 56, 571 (2001).
• 10. Kuo L.C., Assefa H., Brzozowski Z., Sławiński J., Sączewski F., Buolamwini J.K. and Nemati N., J. Med. Chem., 47, 385 (2004).
• 11. Brzozowski Z., Sączewski F., Sanchez T., Gdaniec M. and Neamati N., Bioorg. Med. Chem., 12, 3663 (2004).
• 12. Brzozowski Z., Sączewski F. and Neamati N., Bioorg. Med. Chem., 14, 2985 (2006).
• 13. Brzozowski Z. and Sławiński J., Acta Polon. Pharm., 41, 5 (1984).
• 14. Brzozowski Z. and Sławiński J., Acta Polon. Pharm., 41, 133 (1984).
• 15. Brzozowski Z., Sławiński J., Gajewski F. and Pomarnacka E., Acta Polon. Pharm. DrugRes., 50, 199 (1993).
• 16. Brown R.D. and Kearley R.A., J. Am. Chem. Soc., 72, 2762 (1950).
• 17. Stroh Hans-H. and Scharnow Hans-G., Chem. Ber., 98, 1588 (1965).
• 18. Nobuhide Yahiro, Chem. Lett., 1479 (1982).
• 19. Trepanier D.L., Rickman J.E. and Rudzik A.D., J. Med. Chem., 10, 228 (1967).
• 20. Wieslow O.W., Kieser R., Fine D., Bader J., Shoemaker R.H. and Boyd M.R., J. Natl. Cancer Inst.,81,577(1989).
• 21. Molecular modeling studies were performed at ab initio level using the Hartree-Fock method with 6-31 G** basis set and non-local density functional modules as implemented into TITAN program Version 1,0,5 (2000), Wavefunction Inc. Schrödinger Inc